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1. Introduction  
Lymphoma is the fifth most common cancer type in the Western world, accounting for 
approximately 12,000 cases per annum in the UK alone. Moreover the occurrence of this 
type of cancer has been increasing. The age-adjusted incidence of non-Hodgkin’s lymphoma 
(NHL) in the US for example has increased 74% between 1976 and 2001 (SEER 2005). 
Follicular lymphoma (FL) is the most common form of low grade B-cell lymphoma (75-80% 
of all cases) representing about a third of all NHL cases in the US, and a quarter of all cases 
in Europe (Anderson et al. 1998). FL is characterised by the presence of the t(14;18) 
translocation in 90% of patients associated with up-regulation of the anti-apoptotic protein 
BCL2. Whilst FL tumours are chemo-sensitive, the disease is essentially incurable, with 
patients following a relapsing-remitting clinical course, typically experiencing several 
episodes of disease before eventually becoming refractory to treatment.  
Although indolent, with a median overall survival (OS) of ~10 years, about 30% of FL 
patients undergo high-grade transformation to an aggressive lymphoma that is 
histologically indistinguishable from diffuse large B-cell lympohoma (DLBCL). Transformed 
FL (tFL) patients have a particularly poor outcome with a median survival of <14 months 
(Wrench et al. 2010). The molecular basis of FL transformation is only poorly understood 
and importantly to date there are no reliable biomarkers that can identify FL patients at risk 
of transformation. In this chapter we will review the experimental evidence for the 
involvement of microRNAs in the pathology of FL with particular focus on the 
transformation process.  
2. Follicular lymphoma 
FL is a neoplasm of follicle center B cells (centrocytes) characterized by a (partially) follicular 
growth pattern. FL tumor cells are believed to arise from normal germinal centre–associated 
(GC) B cells as they express the same antigen profile as GC B cells (i.e. CD19, CD20, CD10, 
BCL6, and membrane-bound IgM or IgG), share many morphological features of normal GC 
cells, and are found within a follicular architecture embedded in a network of T cells and 
follicular dendritic cells. In contrast to normal GC cells however, FL tumour cells are 
characterised by the presence of t(14:18) translocation resulting in expression of the anti-
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apoptotic molecule BCL2. This translocation is detectable in approximately 75% of cases by 
traditional karyotyping techniques but in over 90% of cases measured by polymerase chain 
reaction (PCR) (Tsujimoto et al. 1985). Although considered to be an essential feature of FL 
pathology, this genetic insult appears not to be in itself sufficient to cause FL as BCL2 
transgenic mice do not readily develop lymphoma (McDonnell & Korsmeyer 1991; Strasser 
et al. 1993). Furthermore, the t(14;18) translocation is not an uncommon finding in normal B 
cells, being detectable in over 50% of  healthy individuals (Roulland et al. 2006). Therefore, 
whilst the presence of t(14:18) is highly suggestive of FL, it is by no means diagnostic, and 
indeed may be found in other apparently unrelated cases of NHL including 15-30% of 
DLBCL cases (Iqbal et al. 2004). Furthermore about 5% of FL cases lack the t(14:18) 
translocation instead being characterised by a BCL6 translocation t(3;14) and displaying an 
almost exclusive centroblastic morphology (Jaffe et al. 2001).  
FL predominantly affects adults with a median age of 59 years and a male:female ratio of 
1:1.7 (Anderson et al. 1998). Most FL patients already have widespread disease at time of 
presentation, predominantly in the lymph nodes, but FL may also involve the spleen, bone 
marrow, and peripheral blood and occasionally extra-nodal sites such as the gastro-
intestinal tract or skin. Patients may be asymptomatic with slowly progressive 
lymphadenopathy or present with symptomatic complications of advancing tumour growth 
that require treatment. In nearly all survival studies, despite initial responsiveness to 
treatment, most patients relapse, and will eventually die of their disease.  
2.1 Histological transformation of FL tumors 
A percentage of FL patients (10-60% depending on the study) will eventually undergo high 
grade transformation from indolent FL to a much more aggressive tumor that is 
histologically indistinguishable from DLBCL, and is associated with a much poorer 
prognostic outcome. A recent study of 325 patients (median follow-up 15 years) found the 
risk of transformation to be 28% (Montoto et al. 2007). Despite the use of high dose therapy 
for transformed FL (tFL) cases, response rates are still lower than histologically equivalent de 
novo cases of DLBCL with a median survival of just 1.2 years. The molecular mechanisms 
behind this phenomenon, however, are very poorly understood and consequently the 
identification of at-risk patients, who might benefit from up-front high dose treatment 
modalities, remains one of the greatest challenges facing onco-hematologists today. 
Lossos et al identified 671 genes that were aberrantly expressed in at least three of twelve 
paired biopsy samples which fell into two distinct groups; those that had c-myc and its 
target genes up-regulated and those where these genes were down-regulated (Lossos et al. 
2002). Another study of five paired samples identified 36 up-regulated and 66 down-
regulated genes, seven of which were common with the study of Lossos et al (de Vos et al. 
2003). Sixty-seven and 46 genes were found to be up-regulated and down-regulated 
respectively in a series of eleven paired samples analyzed by Elenitoba-Johnson et al 
(Elenitoba-Johnson et al. 2003). Up-regulation of p38BMAPK was confirmed 
immunohistochemically as it was detected in DLBCL cases but not FL or normal GC cells. 
Davies et al examined the gene expression profile of twenty paired lymphoma samples 
taken pre- and post-transformation (Davies et al. 2007). They found that transformation 
proceeded by at least two molecular pathways; one characterized by a cell proliferation 
signature that was associated with recurrent oncogenic abnormalities and a decrease in T 
cell and follicular dendritic cell genes, while the other group showed no increase in 
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proliferation genes and followed an as yet undetermined route. In contrast a gene 
expression study of non-paired patients (24 FL patients who underwent transformation, 22 
FL patients without transformation (after 7 years) and 24 DLBCL patients who had 
previously transformed from FL) found that gene expression was too heterogeneous to 
reliably predict transformation (Glas et al. 2007). They did however report a correlation by 
immunohistochemistry with the spatial distribution to neoplastic follicles and the activation 
of CD4+ T cells and specifically T-helper 1 cells (P>0.05). They did not find any correlation 
with other infiltrating cell populations including CD68+ macrophages or regulatory T cells.  
Additionally, genomic alterations have been demonstrated to be associated with transformation 
of FL. The acquisition of novel mutations in PIM-1, PAX-5, RhoH/TTF and c-MYC genes, due 
to aberrant somatic hypermutation, was found in 5/9 cases that had undergone transformation 
(Rossi et al. 2006). Genomic aberrations were found to be more common in transformed cases of 
DLBCL than non-transformed FL and the alterations -6q16-21 and +7pter-q22 were only found 
in transformed DLBCL but not in follicular lymphoma whereas -4q13-21 was more common in 
transformed than de novo DLBCL (Berglund et al. 2007).  
However, despite intensive research the molecular basis for transformation in FL patients 
remains largely unknown. Recently, ourselves and others, have raised the possibility that 
microRNAs may be important factors in both FL transformation and antecedent FL 
lymphogenesis (Roehle et al. 2008; Lawrie et al. 2009). 
3. MicroRNAs 
MicroRNAs are a recently discovered class of naturally occurring short non-coding RNA 
molecules that regulate eukaryotic gene expression post-transcriptionally. There are now more 
than 900 human microRNAs that have been identified through cloning and/or sequence 
analysis (miRBase- (Griffiths-Jones et al. 2006)), and it is believed some 60% of all human genes 
are a target for microRNA regulation (Friedman et al. 2009). MicroRNAs have been shown to 
play key regulatory roles in virtually every aspect of biology including developmental timing, 
cell differentiation, apoptosis, cell proliferation, metabolism organ development, and 
hematopoiesis (Kim 2005). The potential importance of microRNAs in cancer is implied by the 
finding that the majority of human microRNAs are located at cancer-associated genomic 
regions (Calin et al. 2004), and there is now overwhelming evidence that dysfunctional 
expression of microRNAs is a common, if not ubiquitous, feature of cancer in general and 
lymphoid malignancy in particular (Lawrie 2008; Iorio & Croce 2009).  
Despite the fundamental role that microRNAs appear to play in biology, these molecules 
were unknown to the scientific world until 1993 when lin-4, a C. elegans developmental 
regulator was identified (Lee et al. 1993; Wightman et al. 1993). The significance of this 
finding was not however realised until seven years later when another worm microRNA, 
let-7 was discovered (Reinhart et al. 2000). Unlike lin-4, the sequence of let-7 was found to be 
highly conserved in almost all organisms (Pasquinelli et al. 2000). It was soon realised that 
similar sequences were scattered throughout eukaryotic genomes that were first called 
microRNAs in 2001 (Lee & Ambros 2001).  
3.1 MicroRNA biosynthesis and function 
The majority of human microRNAs are encoded within introns of coding or non-coding 
mRNAs whilst others are located exgenically, within the exons of non-coding mRNAs or 
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within the 3’UTR sequence of mRNA (Rodriguez et al. 2004). MicroRNAs are transcribed as 
5’-capped large polyadenylated transcripts (pri-microRNA) primarily in a Pol II-dependent 
manner (Figure 1), although the involvement of Pol-III transcription has also been 
postulated for microRNAs encoded within Alu repeat sequences (Borchert et al. 2006). 
Approximately 40% of human microRNAs are co-transcribed as clusters encoding up to 
eight distinct microRNA sequences in a single pri-microRNA transcript (Altuvia et al. 2005; 
Hertel et al. 2006). Pri-microRNAs are cleaved within the nucleus by Drosha, an RNaseIII-
type nuclease, to form 60-70 nucleotide hairpin structures (pre-microRNA). Drosha by itself 
possesses little enzymatic activity and requires the cofactor DiGeorge syndrome critical 
region 8 gene (DGCR8) in humans (Pasha in Drosophila) to form the so-called 
microprocessor complex (Yeom et al. 2006). Once produced, the pre-microRNAs are 
 
Fig. 1. Schematic diagram of microRNA biosynthesis and function in animal cells. Pri-
microRNA precursor is transcribed in Pol-II dependent manner and then cleaved by 
microprocessor complex (Drosha/DGCR8) to form hairpin-structure pre-microRNA. Pre-
microRNAs are exported from the nucleus by exportin-5 in a RAN-GTP dependent manner 
where they are cleaved into an asymmetric duplex by action of Dicer and accessory proteins. 
The mature microRNA is loaded into the miRISC complex which binds to cognate 3’UTR 
sequence of target mRNA resulting in either degradation of mRNA, or to blockage of 
translation without mRNA degradation. 
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exported from the nucleus to the cytoplasm by Exportin5 in a Ran-GTP dependent manner 
(Zeng 2006). The cytoplasmic pre-microRNA is further cleaved to form an asymmetric 
duplex intermediate (microRNA: microRNA*) by Dicer, another RNaseIII-type enzyme. 
Similar to Drosha, cofactors such as TRBP and PACT (in humans) are necessary for Dicer 
activity (Lee et al. 2006). The microRNA: microRNA* duplex is in turn loaded into the 
miRISC complex in which Argonaut (Ago) proteins appear to be the key effector molecules. 
The strand that becomes the active mature microRNA appears to be dependent upon which 
has the lowest free energy 5’ end and is retained by the miRISC complex whilst the other 
strand is usually degraded by an unknown nuclease (Khvorova et al. 2003; Schwarz et al. 
2003).  
The loaded miRISC is guided by the mature microRNA sequence (19-24 nucleotide) to 
partially complementary sequences within the 3’UTR (and probably coding sequences and 
5’UTR as well) of the target mRNA, leading to inhibition of translation, transcript 
degradation, or both (Lawrie 2007; Lytle et al. 2007). Although repression of translation 
without mRNA degradation was originally believed to be the modus operandi of animal 
microRNAs, the situation appears to be more complex than previously thought, as there is 
now compelling evidence that microRNAs also effect transcriptional levels through de-
adenylation and/or degradation (Giraldez et al. 2006) and may even positively affect 
translation in some instances (Vasudevan et al. 2007). How translational repression occurs 
remains unclear. It has been suggested that mRNA bound to the microRNA-miRISC 
complex may be sequestered away from the translational machinery in P-bodies that 
additionally act in concert with enzymes to remove the 5’-cap hence preventing translation 
(Liu et al. 2005; Sen & Blau 2005). Alternatively it has been suggested that microRNAs may 
prevent recognition of the 5’cap by translation factors (Pillai et al. 2005).  
4. MicroRNA expression in FL 
The following experimental details were taken in part from previously published research 
(Lawrie, CH et al., 2009). The only other study, as far we are aware, that considers 
microRNA expression in FL, was by Roehle et al which although it included 46 FL samples, 
only measured levels of 153 microRNA probes (compared with 464 microRNA probes in 
this study), and did not consider FL transformation (Roehle et al. 2008). 
4.1 Materials and methods 
4.1.1 Patient material 
Formalin-fixed paraffin-embedded (FFPE) biopsy samples from 98 patients were obtained 
from the Pathology Department of the John Radcliffe Hospital, Oxford, UK. Eighty 
patients were diagnosed histologically and clinically as having DLBCL; 64 de novo 
(DLBCL-de novo) and 16 transformed cases with previously diagnosed FL (DLBCL-t). Of 
the 18 cases of FL used in this study, seven subsequently underwent high grade 
transformation (FL-t) with a median time to transformation of 24 months (range 10-96 
months) from initial diagnosis. The remaining 11 FL cases (FL-nt) had no recorded 
transformation events (median follow-up time 60 months; range 52-132 months). The FL-t 
and DLBCL-t samples were not paired. All FL cases were grade 1 or 2 at time of original 
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diagnosis. All samples were collected at time of initial diagnosis (i.e. prior to treatment) 
with the exception of DLBCL-t cases. Samples had >80% of tumor cells as determined by 
hematoxylin and eosin staining (not shown). Relevant ethical permission was obtained for 
the use of all samples. 
4.1.2 RNA purification and microarray analysis 
Total RNA was purified from four x 20 µm FFPE sections using the Recoverall kit from 
Ambion (Huntington, UK) in accordance with the manufacturers’ instructions. RNA (3 µg) 
were labeled and hybridized to µRNA microarrays as previously described (Lawrie et al. 
2008) using tonsillar material (pooled from twelve healthy individuals) as a common 
reference in a dye-balanced design.  
Image analysis was carried out with BlueFuse software (BlueGnome, Cambridge, UK). Raw 
image data were global median-normalized within arrays and normalized between arrays 
using the LIMMA package (Smyth & Speed 2003). The normalized log ratios (average of 
four replicates per probe) were used for subsequent analysis in Genespring 7.2 (Agilent 
Technologies, CA, US). ANOVA analysis was used to identify microRNAs differentially 
expressed between sample types and P values were adjusted using the Benjamini-Hodgberg 
correction method. Differentially expressed genes were tested for their ability to predict 
sample class using the leave-one-out cross-validation support vector machine (SVM) 
function in Genespring. 
4.2 Results & discussion 
4.2.1 MicroRNA expression is distinct between DLBCL and FL  
In order to investigate differences in microRNA expression between FL and DLBCL 
samples, and because de novo and transformed DLBCL are indistinguishable histologically, 
we initially compared expression in all DLBCL cases (n = 80) with that of all FL cases (n = 
18). Thirty microRNAs were found to be differentially expressed (P < 0.05) (Table 1). 
Expression values of these microRNAs correctly predicted 95/97 (98%) of cases as DLBCL 
or FL by SVM, and clustered the cases distinctly (Fig. 2A).  
The study by Roehle et al identified 10 microRNAs that were differentially expressed 
between FL and DLBCL cases (Roehle et al. 2008). Only two of these microRNAs (miR-150 
and miR-135a) were found to be differentially expressed (P < 0.05) in our patient cohort, 
although another two microRNAs, miR-92 and miR-125b, had P values of < 0.1. These 10 
microRNAs correctly predicted 74/97 (76%) of cases according to diagnosis.  
Roehle’s study, however, compared de novo cases of DLBCL with FL cases that did not 
undergo subsequent transformation. Therefore, in order to compare the data directly we 
used the same sample types (64 DLBCL-de novo and 11 FL-nt cases) to re-analyze the data. 
This resulted in 26 differentially expressed (P < 0.05) microRNAs (Table 2), 14 of which were 
also present in the previous list (Table 1). These microRNAs correctly predicted 73/75 (97%) 
of cases in this cohort (c.f. 60/75 (80%) with the 10 microRNA signature (Roehle et al. 2008)) 
and 92/97 (95%) of cases in the extended cohort. Again, the two sets of samples were found 
to cluster distinctly using the 26-microRNA signature (Fig. 2B).  
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microRNA P value Up Fold change 
hsa-miR-200c 8.20E-08 DLBCL 9.39 
hsa-miR-518a 1.23E-03 DLBCL 3.15 
hsa-miR-638 8.05E-04 DLBCL 3.09 
hsa-miR-205 4.36E-02 DLBCL 2.85 
hsa-miR-223 1.42E-02 DLBCL 2.75 
hsa-miR-573 2.79E-02 DLBCL 2.35 
hsa-miR-135b 3.83E-02 DLBCL 1.63 
hsa-miR-133a 8.65E-03 DLBCL 1.38 
hsa-miR-135a 3.72E-02 DLBCL 1.38 
hsa-miR-451 3.67E-03 DLBCL 1.38 
hsa-miR-27b 2.12E-06 DLBCL 1.21 
hsa-miR-27a 4.62E-07 DLBCL 1.13 
hsa-miR-18b 1.03E-02 DLBCL 0.93 
hsa-miR-199b 3.23E-03 DLBCL 0.83 
hsa-miR-19a 1.20E-02 DLBCL 0.80 
hsa-miR-210 1.10E-02 DLBCL 0.75 
hsa-miR-19b 7.60E-04 DLBCL 0.75 
hsa-miR-99a 9.00E-05 DLBCL 0.72 
hsa-miR-100 1.07E-02 DLBCL 0.51 
hsa-miR-361 3.57E-02 FL 0.58 
hsa-miR-29c 3.07E-02 FL 0.63 
hsa-miR-26a 8.85E-03 FL 0.73 
hsa-miR-29b 4.22E-03 FL 0.76 
hsa-miR-26b 5.50E-03 FL 1.04 
hsa-miR-655 4.76E-02 FL 2.32 
hsa-miR-10b 3.10E-02 FL 2.38 
hsa-miR-634 1.19E-02 FL 2.41 
hsa-miR-593 3.30E-02 FL 2.43 
hsa-miR-28 1.47E-02 FL 2.49 
hsa-miR-150 1.45E-03 FL 3.37 
Table 1. MicroRNAs differentially expressed (P < 0.05) between DLBCL (DLBCL-de novo 
and DLBCL-t) and FL (FL-nt and FL-t) diagnoses. 
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microRNA P value Up Fold change 
hsa-miR-200c 4.58E-06 DLBCL 10.03 
hsa-miR-638 5.30E-04 DLBCL 3.31 
hsa-miR-518a 3.85E-02 DLBCL 2.88 
hsa-miR-199a 1.57E-02 DLBCL 2.67 
hsa-miR-93 3.74E-02 DLBCL 2.64 
hsa-miR-22 1.94E-02 DLBCL 2.46 
hsa-miR-34a 3.92E-02 DLBCL 2.39 
hsa-miR-362 4.68E-02 DLBCL 2.30 
hsa-miR-206 3.93E-02 DLBCL 1.73 
hsa-miR-451 3.23E-03 DLBCL 1.49 
hsa-miR-636 8.55E-03 DLBCL 1.17 
hsa-miR-92 4.05E-02 DLBCL 1.08 
hsa-miR-27b 6.85E-04 DLBCL 1.04 
hsa-miR-199b 1.15E-04 DLBCL 1.03 
hsa-miR-27a 4.03E-04 DLBCL 0.97 
hsa-miR-24 2.04E-02 DLBCL 0.75 
hsa-miR-106a 1.16E-02 DLBCL 0.73 
hsa-miR-20a 2.62E-02 DLBCL 0.67 
hsa-miR-19b 4.95E-03 DLBCL 0.64 
hsa-miR-99a 9.55E-03 DLBCL 0.56 
hsa-miR-18b 3.27E-02 DLBCL 0.54 
hsa-miR-100 1.95E-02 DLBCL 0.43 
hsa-miR-26b 1.88E-02 FL 1.42 
hsa-miR-217 2.84E-02 FL 2.44 
hsa-miR-634 9.50E-04 FL 2.54 
hsa-miR-150 4.55E-02 FL 3.46 
Table 2. MicroRNAs differentially expressed (P < 0.05) between de novo DLBCL and non-
transforming FL cases. Members of the miR-17-92 cluster (and homologous clusters) are 
depicted in bold type. 
Interestingly, six of the microRNAs that were identified as being up-regulated in DLBCL-de 
novo cases compared to FL-nt are encoded by the miR-17-92 and/or homologous clusters 
(average fold-increase of 1.05 (range 0.54-2.64)) (He et al. 2005). The other four microRNAs 
encoded by these clusters, miR-17-5p, miR-19a, miR-25 and miR-106b, had P values of 0.067, 
0.087, 0.064 and 0.391 respectively. The miR-17-92 cluster is encoded at the 13q31 locus, a 
region commonly amplified in lymphomas and ectopic expression of miR-17-92 greatly 
accelerated lymphogenesis in a murine model (He et al. 2005). Moreover, direct binding of 
the c-myc protein up-regulates miR-17-92 expression (O'Donnell et al. 2005) and over-
expression of c-myc has been demonstrated in the majority (66.6%) of DLBCL cases (Aref et 
al. 2004), which has also been associated with poorer outcome (Pagnano et al. 2001). An 
increased level of this cluster in DLBCL compared to FL is consistent with a more aggressive 
clinical phenotype of DLBCL.  
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Fig. 2. Cluster analysis of microRNAs differentially expressed between FL and DLBCL. 
(A) All DLBCL cases (n = 80) and FL cases (n = 18). (B) Only de novo cases (DLBCL-de novo 
(n = 64)) and cases of FL that did not undergo transformation (FL-nt (n = 11)). Reproduced 
from (Lawrie et al. 2009). 
4.2.2 Histological transformation of FL is associated with changes in microRNA 
expression 
To investigate whether changes in microRNA expression were associated with 
transformation we first looked at differences between de novo (DLBCL-de novo (n = 64) and 
transformed (DLBCL-t (n = 16)) cases of DLBCL. Fourteen microRNAs (Table 3) were found 
to be differentially expressed (P < 0.05). These microRNAs correctly predicted 
transformation status in 73/80 (91%) of samples. Only one of these was up-regulated in 
DLBCL-t (miR-491). Four of the microRNAs down-regulated in DLBCL-t are encoded by the 
miR-17-92 cluster suggesting an involvement of the cluster in high grade transformation. An 
alternative explanation is that because the cluster was also found to be down-regulated in 
FL compared with DLBCL-de novo (Table 2), the expression pattern of these microRNAs in 
DLBCL-t cases reflects that of antecedent FL. This latter hypothesis is consistent with gene 
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expression profile studies that found that DLBCL-t cases were more closely related to FL 
than DLBCL-de novo cases (Lossos et al. 2002).  
 
microRNA P value Up Fold change 
hsa-miR-491 2.11E-02 trans 2.54 
hsa-miR-27a 3.90E-02 de novo 0.47 
hsa-miR-19b 3.77E-03 de novo 0.60 
hsa-miR-25 3.84E-02 de novo 0.67 
hsa-miR-18a 1.24E-02 de novo 0.72 
hsa-miR-636 2.73E-02 de novo 1.06 
hsa-miR-92 1.94E-02 de novo 1.14 
hsa-miR-621 2.29E-02 de novo 1.98 
hsa-miR-526c 2.44E-02 de novo 2.38 
hsa-miR-766 2.75E-02 de novo 2.58 
hsa-miR-299-5p 4.76E-02 de novo 2.61 
hsa-miR-380-3p 5.94E-03 de novo 2.65 
hsa-miR-129 2.98E-02 de novo 2.70 
hsa-miR-588 9.05E-03 de novo 2.80 
 
Table 3. MicroRNAs differentially expressed (P < 0.05) between DLBCL-de novo and 
DLBCL-t cases. 
Next we compared FL cases that subsequently underwent high grade transformation (FL-t 
(n = 7)) with cases that did not (FL-nt (n = 11)). Six microRNAs were differentially expressed 
(P < 0.05) between these two groups (Table 4), whose expression levels correctly predicted 
16/18 (89%) of cases.  
 
microRNA P value Up   
hsa-miR-223 1.43E-03 FL-nt 1.51 
hsa-miR-217 5.56E-03 FL-nt 2.56 
hsa-miR-222 1.41E-02 FL-t 1.26 
hsa-let-7i 2.09E-02 FL-t 2.45 
hsa-miR-221 2.34E-02 FL-t 3.14 
hsa-let-7b 2.46E-02 FL-t 3.18 
 
Table 4. MicroRNAs differentially expressed (P < 0.05) between FL cases that subsequently 
underwent high grade transformation (FL-t) and those that did not (FL-nt). Median follow-
up time 60 months (range 52-132 months). 
Let-7b, let-7i, miR-221 and miR-222 were up-regulated in FL-t whilst miR-223 and miR-217 
were down-regulated (Fig. 3). Members of the let-7 family have been shown to target c-myc 
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expression in Burkitt lymphoma (Sampson et al. 2007) and decreased c-myc expression has 
been associated with high grade transformation of FL to DLBCL (Lossos et al. 2002). 
Interestingly, up-regulated microRNAs miR-221 and miR-222 target the tumor suppressor 
molecule p27(Kip1) (le Sage et al. 2007) whilst down-regulated miR-223 has been shown to 
target Stathmin, a known oncogene (Alli et al. 2007). Although the number of cases in this 
analysis was small, and requires further validation, these data open up the exciting 
possibility that microRNA expression could be used to predict FL patients at risk of 
transformation that could benefit from an up-front aggressive therapy regimen.    
 
 
 
 
 
Fig. 3. Expression levels of microRNAs differentially expressed between FL-t and FL-nt 
cases. P values were calculated by independent t-test. Reproduced from (Lawrie et al. 2009). 
5. Conclusion 
In this chapter we have discussed some of the clinico-scientific issues pertaining to follicular 
lymphoma and the role that microRNAs may play in both its pathogenesis and in particular 
histological high grade transformation. As is outlined in this article there are in fact only two 
pieces of research published to date that have investigated microRNA expression in FL, and 
hence some caution should be applied when drawing conclusions about the role/potential 
of specific microRNAs in this disease, as clearly much more research is required. 
Nonetheless, these studies do present some interesting insights and offer the tantalizing 
possibility that microRNAs may deliver novel biomarkers that can identify FL patients at 
risk of transformation where other molecular techniques have failed. 
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